Open AccessRefractory immune thrombocytopenia (ITP) with suspected Evans syndrome requiring quadruple therapy
Author(s) -
Oluwatosin Bewaji,
Preetha Kandaswamy,
Ganesh Maniam,
Smita Bhaskaran,
Samer Zaid Kaylani
Publication year - 2020
Publication title -
journal of rare diseases and orphan drugs
Language(s) - English
Resource type - Journals
ISSN - 2766-9696
DOI - 10.36013/jrdod.v1i.31
Subject(s) - evans syndrome , immune thrombocytopenia , medicine , autoimmune hemolytic anemia , refractory (planetary science) , autoimmune thrombocytopenia , first line therapy , anemia , pediatrics , surgery , immunology , platelet , physics , astrobiology
Immune thrombocytopenia (ITP) is a common cause of acquired thrombocytopenia in children, second only to chemotherapy-induced thrombocytopenia.[1] Most patients respond well to first line therapies, however about there is a high rate of relapse in initially responsive patients.[2] We report a case of recurrent severe form of ITP who failed a re-trial of first line therapies and required second line treatments via a quadruple therapy of immunosuppressants. This case is not only unique due to the aggressive treatment required, but also because patient also had investigation results suggestive of autoimmune hemolytic anemia (AIHA) raising suspicion of Evans Syndrome.